These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32251770)

  • 1. Improved melanoma suppression with target-delivered TRAIL and Paclitaxel by a multifunctional nanocarrier.
    Huang S; Zhang Y; Wang L; Liu W; Xiao L; Lin Q; Gong T; Sun X; He Q; Zhang Z; Zhang L
    J Control Release; 2020 Sep; 325():10-24. PubMed ID: 32251770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two methods for tumour-targeting peptide modification of liposomes.
    Huang SQ; Zhang HM; Zhang YC; Wang LY; Zhang ZR; Zhang L
    Acta Pharmacol Sin; 2023 Apr; 44(4):832-840. PubMed ID: 36271156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma.
    Shi K; Li J; Cao Z; Yang P; Qiu Y; Yang B; Wang Y; Long Y; Liu Y; Zhang Q; Qian J; Zhang Z; Gao H; He Q
    J Control Release; 2015 Nov; 217():138-50. PubMed ID: 26368312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer.
    Min SY; Byeon HJ; Lee C; Seo J; Lee ES; Shin BS; Choi HG; Lee KC; Youn YS
    Int J Pharm; 2015 Oct; 494(1):506-15. PubMed ID: 26315118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Water-Borne Polyurethane Nanomicelles for Cancer Chemotherapy: Higher Efficiency of Folate Receptors Than TRAIL Receptors in a Cancerous Balb/C Mouse Model.
    Ajorlou E; Khosroushahi AY; Yeganeh H
    Pharm Res; 2016 Jun; 33(6):1426-39. PubMed ID: 26908046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Kurbanov BM; Geilen CC; Fecker LF; Orfanos CE; Eberle J
    J Invest Dermatol; 2005 Nov; 125(5):1010-9. PubMed ID: 16297203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel enhances tumoricidal potential of TRAIL via inhibition of MAPK in resistant gastric cancer cells.
    Li L; Wen XZ; Bu ZD; Cheng XJ; Xing XF; Wang XH; Zhang LH; Guo T; Du H; Hu Y; Fan B; Ji JF
    Oncol Rep; 2016 May; 35(5):3009-17. PubMed ID: 26986870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo.
    Zhan C; Wei X; Qian J; Feng L; Zhu J; Lu W
    J Control Release; 2012 Jun; 160(3):630-6. PubMed ID: 22410115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokines from the tumor microenvironment modulate sirtinol cytotoxicity in A549 lung carcinoma cells.
    Pal S; Shankar BS; Sainis KB
    Cytokine; 2013 Oct; 64(1):196-207. PubMed ID: 23972545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel ginsenoside-based multifunctional liposomal delivery system for combination therapy of gastric cancer.
    Hong C; Wang D; Liang J; Guo Y; Zhu Y; Xia J; Qin J; Zhan H; Wang J
    Theranostics; 2019; 9(15):4437-4449. PubMed ID: 31285771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
    Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
    Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system.
    Zhang Q; Tang J; Fu L; Ran R; Liu Y; Yuan M; He Q
    Biomaterials; 2013 Oct; 34(32):7980-93. PubMed ID: 23891517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma.
    Yuan M; Qiu Y; Zhang L; Gao H; He Q
    Drug Deliv; 2016 May; 23(4):1171-83. PubMed ID: 26036724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
    Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promotion of TRAIL/Apo2L-induced apoptosis by low-dose interferon-β in human malignant melanoma cells.
    Kazaana A; Sano E; Yoshimura S; Makita K; Hara H; Yoshino A; Ueda T
    J Cell Physiol; 2019 Aug; 234(8):13510-13524. PubMed ID: 30613977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4.
    Kurbanov BM; Fecker LF; Geilen CC; Sterry W; Eberle J
    Oncogene; 2007 May; 26(23):3364-77. PubMed ID: 17160022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The essential role of the mitochondria-dependent death-signaling cascade in chemotherapy-induced potentiation of Apo2L/TRAIL cytotoxicity in cultured thoracic cancer cells: amplified caspase 8 is indispensable for combination-mediated massive cell death.
    Nguyen DM; Yeow WS; Ziauddin MF; Baras A; Tsai W; Reddy RM; Chua A; Cole GW; Schrump DS
    Cancer J; 2006; 12(4):257-73. PubMed ID: 16925970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH-Sensitive liposomal nanocarrier for the synergistic treatment of melanoma.
    Reddy TL; Garikapati KR; Reddy SG; Reddy BV; Yadav JS; Bhadra U; Bhadra MP
    Sci Rep; 2016 Oct; 6():35223. PubMed ID: 27786239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.